tbuckley/cabot-search huggingface dataset:
Brain malignancies: Glioblastoma and brain metastases
Authors: Tamara T. Lah, Metka Novak, Barbara Breznik
Journal: Seminars in Cancer Biology (2019)

Brain, the major organ of the central nervous system controls and processes most of body activities. Therefore, the most aggressive brain tumor - glioblastoma and metastases from other organs to the brain are lethal leaving the patients with very short time of survival. The brain tissue landscape is very different from any other tissues and the specific microenvironment, comprising stem cells niches and blood-brain barrier, significantly influences the low rate of glioblastoma metastasis out of the brain, but better accommodates brain-invading cancer. In contrast to low frequency (0.5%) of all glioblastoma metastases, 10%-45% of other primary cancers do metastasize to the brain. This review addresses general cellular and molecular pathways that are to some extent similar in both types of metastases, involving circulating tumor cells (CTCs) with cancer stem cells (CSCs) characteristics, and metastatic niches. The invasion is a dynamic process involving reversible epithelial-to-mesenchymal (EMT) cell process, creating a transient gradient state that is inter-connected with epigenetic plasticity of the metastasizing (m)CSCs. These cells can switch between stationary, low proliferating/dormant state to a migratory, mesenchymal-like state. Settling in their respective niches as dormant CSCs in the secondary organ is a common feature in all types of metastases. In glioblastoma metastasis, the malignant mGSC cells express markers of mesenchymal GSC subtype (MES-GSC), such as CD44 and YK-40 and their major obstacle seems to be propagating in the in various organs' microenvironments, different from the niches that home GSCs in the primary glioblastoma. Focusing on one stromal component in the glioblastoma niches, the mesenchymal stem cells (MSCs), we report herein on their differential effects on glioblastoma cells, highly depending on their genetic subtype. On the other hand, in brain metastases, the major hindrance to metastatic progression of mCSCs seem to be crossing the blood-brain-barrier. Novel therapeutic approaches for brain metastases from various cancer types are advancing slowly, and the general trends involve targeting metastatic sub-clones and selective determinants of their niches. The update on the four most common brain metastases from lung, breast, melanoma and colorectal carcinoma is presented.
P1.09-12 In-Situ Hybridization Visual Scoring of Epigenetic Imprinting Genes Improves Early Diagnosis and Grading of Lung Cancers
Authors: R. Yung, T. Cheng, X. Li, X. Wang, H. Si, P. Zhao, R. Shen, J. Zhou, H. Yu, M. Ding, S. Lu, N. Zhou, C. Bai
Journal: Journal of Thoracic Oncology (2019)
Sixty seconds on . . . toast
Authors: Abi Rimmer
Journal: BMJ (2019)

Not that kind of toast. We’re talking about the humblest of foods: toasted bread. Prue Leith, celebrity chef and adviser to the government’s review of hospital food,12 said that hospitals aren’t serving enough of it.

Too right. Speaking at the Dorchester Literary Festival in Dorset, Leith said that the one thing people most criticised about the NHS was the …
Young Women and Oral Human Papillomavirus—Vaccination Is Associated With Protection
Authors: Rachel A. Katzenellenbogen, Kenneth H. Fife
Journal: JAMA Network Open (2019)

Nicolas F. Schlecht, PhD; Martin Masika, MD; Angela Diaz, MD, PhD; Anne Nucci-Sack, MD; Anthony Salandy, PhD; Sarah Pickering, MPH; Howard D. Strickler, MD, MPH; Viswanathan Shankar, DrPH; Robert D. Burk, MD
P1.12-16 LMW Heparin Adherence and Effects on Survival Within a Randomized Phase III Lung Cancer Trial (RASTEN)
Authors: E. Gezelius, P. Bendahl, K. Gonçalves De Oliveira, L. Ek, B. Bergman, J. Sundberg, K. Strandberg, R. Kraemer, M. Belting
Journal: Journal of Thoracic Oncology (2019)
Experimental Chlamydia Vaccine Shows Promise
Authors: Anita Slomski
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MA11.04 Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226
Authors: R. Juergens, P. Ellis, D. Tu, D. Hao, S. Laurie, M. Mates, G. Goss, J. Goffin, P. Bradbury, M. Tehfe, C. Kollmansberger, P. Brown-Walker, M. Smoragiewicz, M. Tsao, L. Seymour
Journal: Journal of Thoracic Oncology (2019)
P1.16-44 Multiple Primary Cancers (MPC) in a Cohort of Lung Cancer (LC) Patients (P): Incidence and Clinical Features
Authors: C. Erasun Lecuona, A. Gonzalez, A. Esteve, M. Domenech, E. Felip, M. Cucurull, L. Angelats, S. España, A. Ferrando, A. Plaja, L. Notario, A. Pous, T. Moran, E. Carcereny
Journal: Journal of Thoracic Oncology (2019)
P2.03-32 Metastatic Lymph Nodes as High Immunogenicity Media for Perioperative Immunotherapy in Locally Advanced NSCLC
Authors: C. Zhang, S. Liu, J. Su, X. Gao, L. Chang, Y. Guan, H. Tu, Q. Zhou, J. Yang, X. Yang, X. Zhang, Y. Wu, W. Zhong
Journal: Journal of Thoracic Oncology (2019)
P1.04-07 Immune Suppressive Microenvironment and Highly Clonal Concordance of TCR Repertoire in Brain Metastases from Non-Small Cell Lung Cancer
Authors: Y. Kudo, C. Haymaker, J. Zhang, A. Reuben, D. Duose, J. Fujimoto, S. Roy-Chowdhuri, L. Solis, H. Dejima, E. Parra Cuentas, B. Mino, N. Ikeda, R. Luthra, D. Gibbons, J. Zhang, F. Lang, J.J. Lee, J. Huse, H. Kadara, I. Wistuba
Journal: Journal of Thoracic Oncology (2019)
P2.14-47 Real-World Multicenter Experience of First-line Afatinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Authors: C.K. Liam, C. Chai, G. Ho, A. Alip, M.I.A. Wahid, M.M. Abdullah, Y.C. Foo, S.H. How, A. Zaatar, K.S. Lam, K.W. Leong, J.S.H. Low, M. Md Yusof
Journal: Journal of Thoracic Oncology (2019)
P1.01-20 The Association Between BRAF Mutation Class and Clinical Features in BRAF-Mutant Chinese Non-Small Cell Lung Cancer Patients
Authors: Q. Lin, H. Zhu, Y. Li, H. Zhang, H. Ding, J. Qian, H. Han-Zhang, J. Lin, J. Xiang
Journal: Journal of Thoracic Oncology (2019)
MA20.11 Surgical Treatment for Metastatic Lung Tumors from Sarcomas of Soft Tissue and Bone
Authors: H. Yamamoto, K. Namba, H. Yamamoto, T. Toji, J. Soh, K. Shien, K. Suzawa, T. Kurosaki, S. Ohtani, M. Okazaki, S. Sugimoto, M. Yamane, K. Takahashi, T. Kunisada, T. Oto, S. Toyooka
Journal: Journal of Thoracic Oncology (2019)
P2.04-84 NSCLC Survival Expectancy for Patients Treated with Docetaxel/Nintedanib in the SENECA Trial and Previous Immunotherapy
Authors: E. Capelletto, G. Osman, A. Morabito, R. Chiari, F. Grossi, M. Tiseo, F. Di Costanzo, A. Delmonte, G. Romano, A. Misino, V. Scotti, V. Gregorc, S. Pisconti, M. Bonomi, A. Del Conte, L. Ciuffreda, I. Colantonio, E. Bria, S. Ricciardi, A. Manzo, G. Metro, A. Morelli, R. Critelli, I. Stura, G. Migliaretti, S. Novello
Journal: Journal of Thoracic Oncology (2019)
The relationship between mucin-depleted foci stained with Alcian bleu and beta-catenin accumulated crypts in rat colon carcinogenesis induced by 1,2-dimethylhydrazine dihydrochloride
Authors: Yasushi Ichikawa, Satoshi Hasegawa, Kaori Kubota, Shuji Saito, Shoichi Fujii, Shingo Hasegawa, Hideyuki Ike, Shigeo Ohki, Takashi Ishikawa, Nobuyoshi Momiyama, Kaoru Miyazaki, Hiroshi Shimada
Journal: Cancer Research (2005)

3924  Background: Laterally spreading tumor (LSTs) means flat colorectal tumor, which extend laterally along the colonic wall. LST includes both of adenomatous and cancerous lesions. The mechanism of its lateral growth or of carcinogenesis is still unclear. In the study, we evaluated the clinicopathologic characteristics of LST in comparison with polypoid-type colorectal tumors (PPT). Materials and Methods: Twenty LSTs (including 10 adenomatous LSTs; aLST and 6 cancerous LST; cLST) and 16 PPTs (including 11 adenomatous PPT; aPPT and 4 cancer in adenoma PPT; cPPT) were endoscopically or operatively resected and utilized for histopathologic examinations. We examined immunohistochemical staining for beta-catenin (clone14, Transduction Laboratories), E-cadherin (BV-6, CHEMICON), MMP-9 (56-2A4, Fuji-Chemi. Co) and type IVcollagen (CIV 22, DAKO)in each macroscopic types. Results: 1) “Two Layer Structure”: We observed frequently the front formation between a superficial neoplastic cell and a deep part of normal mucosal epithelial cell in a same crypt in LSTs, and named it ‘two layer structure’. In aPPTs, the “two layer structure” was detected in the 1 or 2 pits at the edge of lesions, however, in aLSTs, ‘two layer structure’ was found not only at the edge but also at the center of lesions and was detected more frequently and continuously (2or more pits) in aLSTs. Interestingly, in cLSTs, “two layer structure” was frequently and continuously detected. 2) Immunohistochemistry: The expression of beta-catenin and E-cadherin, the low expression of MMP-9 and the continuous expression of type IV collagen along the basement membrane were observed not only in aLST and aPPTs, but also in cLSTs. On the other hands, nuclear accumulation of beta-catenin, the loss of expression of E-cadherin, the high expression of MMP-9 and discontinuous expression of type IV collagen were observed in cPPTs. Discussion: ‘Two layer structure’ is considered to be related with the morphological feature of lateral growth in LSTs. In polypoid type tumors, non-invasive cancer in adenoma already expresses MMP-9 and lacks the basement membrane. On the other hands, cLSTs do not reveal MMP-9 and keep the basement membrane around the lesions. LSTs had preserved the functions of normal colorectal mucosa even in cancers.
P1.14-24 Characterization of Acquired Receptor Tyrosine Kinase Fusions as Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors
Authors: H. Xu, Y. Shu, H. Jian, J. Shen, J. Xiang, H. Li, B. Li, T. Zhang, L. Zhang, X. Mao
Journal: Journal of Thoracic Oncology (2019)
EP1.16-27 Observational Study to Investigate the Implementation Rate of Re-Biopsy in EGFR-TKI-Resistant Patients (NLCTG1602)
Authors: K. Koyama, K. Nozaki, S. Shoji, J. Koshio, Y. Hayashi, D. Ishikawa, T. Miyabayashi, M. Okajima, T. Ota, T. Tanaka, N. Matsumoto, T. Abe, K. Sato, S. Miura, H. Tanaka, K. Ichikawa, R. Kondo, S. Watanabe, T. Kikuchi
Journal: Journal of Thoracic Oncology (2019)
P2.03-03 Landscape of Gene Fusions in Lung Adenocarcinoma Patients with Minimal Cigarette Exposure Identified on Malignant Pleural Effusions
Authors: M. Saigi, E. Pros, J.J. Alburquerque Béjar, I. Català, S. Verdura, R. Palmero Sánchez, M. Jove, E. Nadal, M. Sanchez-Cespedes
Journal: Journal of Thoracic Oncology (2019)
MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC
Authors: G. Woodard, V. Ding, I. Kim, K. Jones, G. Chavez, G. Haro, J. Kratz, M. Mann, J. Rotow, C. Blakely, D. Jablons
Journal: Journal of Thoracic Oncology (2019)
EP1.03-33 CD26/DPP4 as a Novel Prognostic Marker for Lung Adenocarcinoma
Authors: J. Jang, M. Haberecker, A. Curioni, F. Janker, A. Soltermann, I. Gil-Bazo, I. Hwang, K. Kwon, W. Weder, W. Jungraithmayr
Journal: Journal of Thoracic Oncology (2019)
Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity
Authors: Kristopher K. Short, Shannon M. Miller, Lois Walsh, Van Cybulski, Hélène Bazin, Jay T. Evans, David Burkhart
Journal: Journal of Controlled Release (2019)
Beclin-1 as a neutrophil-specific immune checkpoint
Authors: Yu-Lin Su, Marcin Kortylewski
Journal: Journal of Clinical Investigation (2019)

Neutrophils are early wound healing and inflammation regulators that, due to functional plasticity, can adopt either pro- or antitumor functions. Until recently, beclin-1 was a protein known mainly for its role as a critical regulator of autophagy. In this issue of the JCI, Tan et al. describe the effects of the beclin-1 conditional myeloid cell-specific deletion in mice, in which immunostimulation resulted in hypersensitive neutrophils. The chronic proinflammatory effect of these neutrophils triggered spontaneous B cell malignancies to develop. Such tumorigenic effects were mediated primarily by IL-21 and CD40 signaling, leading to the upregulation of tolerogenic molecules, such as IL-10 and PD-L1. The authors went on to examine samples derived from patient lymphoid malignancies and showed that beclin-1 expression in neutrophils positively correlated with pre-B cell leukemia/lymphoma. Overall, the study provides an elegant model for neutrophil-driven carcinogenesis and identifies potential targets for immunotherapy of B cell malignancies.
Developmental Toxicity Assessment of Piperonyl Butoxide Exposure Targeting Sonic Hedgehog Signaling and Forebrain and Face Morphogenesis in the Mouse: An <i>in Vitro</i> and <i>in Vivo</i> Study
Authors: Joshua L. Everson, Miranda R. Sun, Dustin M. Fink, Galen W. Heyne, Cal G. Melberg, Kia F. Nelson, Padydeh Doroodchi, Lydia J. Colopy, Caden M. Ulschmid, Alexander A. Martin, Matthew T. McLaughlin, Robert J. Lipinski
Journal: Environmental Health Perspectives (2019)

Background: Piperonyl butoxide (PBO) is a pesticide synergist used in residential, commercial, and agricultural settings. PBO was recently found to inhibit Sonic hedgehog (Shh) signaling, a key developmental regulatory pathway. Disruption of Shh signaling is linked to birth defects, including holoprosencephaly (HPE), a malformation of the forebrain and face thought to result from complex gene–environment interactions. Objectives: The impact of PBO on Shh signaling in vitro and forebrain and face development in vivo was examined. Methods: The influence of PBO on Shh pathway transduction was assayed in mouse and human cell lines. To examine its teratogenic potential, a single dose of PBO (22–1,800mg/kg) was administered by oral gavage to C57BL/6J mice at gestational day 7.75, targeting the critical period for HPE. Gene–environment interactions were investigated using Shh+/− mice, which model human HPE-associated genetic mutations. Results: PBO attenuated Shh signaling in vitro through a mechanism similar to that of the known teratogen cyclopamine. In utero PBO exposure caused characteristic HPE facial dysmorphology including dose-dependent midface hypoplasia and hypotelorism, with a lowest observable effect level of 67mg/kg. Median forebrain deficiency characteristic of HPE was observed in severely affected animals, whereas all effective doses disrupted development of Shh-dependent transient forebrain structures that generate cortical interneurons. Normally silent heterozygous Shh null mutations exacerbated PBO teratogenicity at all doses tested, including 33mg/kg. Discussion: These findings demonstrate that prenatal PBO exposure can cause overt forebrain and face malformations or neurodevelopmental disruptions with subtle or no craniofacial dysmorphology in mice. By targeting Shh signaling as a sensitive mechanism of action and examining gene–environment interactions, this study defined a lowest observable effect level for PBO developmental toxicity in mice more than 30-fold lower than previously recognized. Human exposure to PBO and its potential contribution to etiologically complex birth defects should be rigorously examined. https://doi.org/10.1289/EHP5260
P1.04-14 Early Changes in Plasma CXCL2 and MMP2 Levels Predicts the Response to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer
Authors: N. Matsuo, K. Azuma, K. Murotani, H. Ishii, T. Tokito, K. Yamada, Y. Shibata, T. Shimokawaji, Y. Nakahara, T. Kondo, T. Kato, H. Saito, K. Yamada, T. Sasada, T. Hoshino
Journal: Journal of Thoracic Oncology (2019)
EP1.11-08 Ultra-High-Resolution CT to Project the Detailed Components in Nodules; Fat Components in Pulmonary Hamartomas
Authors: D. Takenaka, A. Higashida, C. Tanaka, E. Matsushiro, T. Hashimoto, H. Maeda, S. Sakamoto, Y. Ohno
Journal: Journal of Thoracic Oncology (2019)
P2.04-46 Tolerability and Treatment-Related Adverse Events of Upfront Pembrolizumab Combination Regimens in Advanced NSCLC Patients
Authors: N. Jahan, K. Thein, A. Sultan, S. Swarup, F. Mogollon-Duffo, N. Adhikari, M. Arevalo, T. Htut, T. Naing, N. D’Cunha, S. Rehman, F. Hardwicke, L. Tijani
Journal: Journal of Thoracic Oncology (2019)
MA11.01 Multifactorial Model to Predict Response to PD-(L)1 Blockade in Patients with High PD-L1 Metastatic Non-Small Cell Lung Cancer
Authors: K. Arbour, M. Oprescu, J. Hakim, H. Rizvi, M. Leiserson, M. Ginsburg, A. Plodkowski, J. Sauter, I. Preeshagul, S. Gillett, P. Rosenfield, L. Mackey, M. Dudik, M. Hellmann
Journal: Journal of Thoracic Oncology (2019)
EP1.14-08 Irreversible Severe Cardiotoxicities Except for QTc Interval Prolongation Associated with Osimertinib
Authors: K. Kunimasa, M. Kimura, T. Inoue, M. Tamiya, K. Nishino, F. Imamura, T. Kumagai
Journal: Journal of Thoracic Oncology (2019)
P2.01-02 CANOPY-A: A Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC
Authors: E. Garon, A. Ardizzoni, F. Barlesi, B.C. Cho, P. De Marchi, Y. Goto, S. Lu, L. Paz-Ares, D. Spigel, M. Thomas, B. Mookerjee, P. Arratia, J. Baum, Z. Zewen, J. Yang
Journal: Journal of Thoracic Oncology (2019)
EP1.17-31 30 Days Major Morbidity and Mortality After Lung Cancer Surgery. Outcomes of Five Years in a Single Center Experience
Authors: F. Caushi, D. Xhemalaj, I. Skenduli, S. Bala, R. Isufi, A. Mezini, H. Hafizi, O. Nuredini, A. Hatibi, A. Cani
Journal: Journal of Thoracic Oncology (2019)
OA07.02 LKB1 Mutations in Metastatic Non-Small Cell Lung Cancer (mNSCLC): Prognostic Value in the Real World
Authors: A. Golozar, J. Collins, K. Fraeman, B. Nordstrom, R. Mcewen, N. Shire, B. Higgs
Journal: Journal of Thoracic Oncology (2019)
P2.14-34 Tyrosine-Kinase Inhibitors (TKI) in First-Line Treatment of 470 Patients with Non-Small Cell Lung Cancer (NSCLC) from the Czech Republic
Authors: J. Skřičková, P. Májková, M. Bařinová, M. Pešek, V. Kolek, I. Grygárková, O. Fischer, L. Koubková, M. Černovská, L. Havel, J. Roubec, M. Hrnčiarik, M. Zemanová, D. Sixtová, M. Šatánková, A. Benejová, P. Opálka, J. Krejčí, H. Čoupková, M. Tomíšková, Z. Merta
Journal: Journal of Thoracic Oncology (2019)
Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria
Authors: C Mircea S Tesileanu, Linda Dirven, Maarten M J Wijnenga, Johan A F Koekkoek, Arnaud J P E Vincent, Hendrikus J Dubbink, Peggy N Atmodimedjo, Johan M Kros, Sjoerd G van Duinen, Marion Smits, Martin J B Taphoorn, Pim J French, Martin J van den Bent
Journal: Neuro-Oncology (2019)

The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) has recommended that isocitrate dehydrogenase 1 and 2 wildtype (IDH1/2wt) diffuse lower-grade gliomas (LGGs) World Health Organization (WHO) grade II or III that present with (i) a telomerase reverse transcriptase promoter mutation (pTERTmt), and/or (ii) gain of chromosome 7 combined with loss of chromosome 10, and/or (iii) epidermal growth factor receptor (EGFR) amplification should be reclassified as diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV (IDH1/2wt astrocytomas WHO IV). This paper describes the overall survival (OS) of IDH1/2wt astrocytoma WHO IV patients, and more in detail patients with tumors with pTERTmt only.In this retrospective multicenter study, we compared the OS of 71 IDH1/2wt astrocytomas WHO IV patients, with radiological characteristics of LGGs, with the OS of 197 IDH1/2wt glioblastoma patients. Moreover, we compared the OS of 22 pTERTmt only astrocytoma patients with the OS of the IDH1/2wt glioblastoma patients.Median OS was similar for IDH1/2wt astrocytoma WHO IV patients (23.8 mo) and IDH1/2wt glioblastoma patients (19.2 mo) (Cox proportional hazards model: hazard ratio [HR] 1.27, 95% CI: 0.85-1.88, P = 0.242). OS was also similar in patients with IDH1/2wt astrocytomas WHO IV, pTERTmt only, and IDH1/2wt glioblastomas (HR 1.15, 95% CI: 0.64-2.10, P = 0.641).The presented data confirm the cIMPACT-NOW recommendation and we propose that IDH1/2wt astrocytomas WHO IV in the absence of other qualifying mutations should be classified as IDH1/2wt glioblastomas.
P2.11-17 Analysis of Lung Adenocarcinoma EGFR Mutation by LAMP Method: Comparison with PCR Method and Identification of a Novel Exon19 Deletion Mutation
Authors: S. Horiuchi, Y. Saito, H. Morooka, T. Ibi, N. Takahashi, T. Ikeya, E. Hoshi, Y. Shimizu
Journal: Journal of Thoracic Oncology (2019)
P1.16-46 Genetic Testing Patterns, Treatment Characteristics, and Overall Survival in ALK-Positive Metastatic NSCLC Patients Treated with Ceritinib
Authors: J. Mazieres, M. Ahn, C. Chouaid, A. Kron, J. Wolf, R. Goyal, K. Davis, M. Perrinjaquet, T. Pham, S. Knoll
Journal: Journal of Thoracic Oncology (2019)
P2.04-82 Discontinuation of Anti-PD-1/PD-L1 Antibody Therapy in the Absence of Disease Progression: Clinical Outcomes in Advanced NSCLC
Authors: N. Minatta, M. Bluthgen, M. Rizzo, M. Rizzi, A. Kuzminin, G. Recondo, M. Faura, M. Naveira, A. Perfetti, M. Cerini, L. Lupinacci
Journal: Journal of Thoracic Oncology (2019)
Comprehensive Benchmarking and Integration of Tumor Microenvironment Cell Estimation Methods
Authors: Alejandro Jiménez-Sánchez, Oliver Cast, Martin L. Miller
Journal: Cancer Research (2019)

Various computational approaches have been developed for estimating the relative abundance of different cell types in the tumor microenvironment (TME) using bulk tumor RNA data. However, a comprehensive comparison across diverse datasets that objectively evaluates the performance of these approaches has not been conducted. Here, we benchmarked seven widely used tools and gene sets and introduced Consensus
P2.04-31 Immune Phenotypic Biomarkers in Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Chemoradiation and Atezolizumab
Authors: E. Cohen, H. Gao, S. Tin, Q. Wu, J. He, Y. Qiao, J. Heymach, A. Tsao, J. Reuben, S. Lin
Journal: Journal of Thoracic Oncology (2019)
CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer
Authors: Brooke A. Pereira, Claire Vennin, Michael Papanicolaou, Cecilia R. Chambers, David Herrmann, Jennifer P. Morton, Thomas R. Cox, Paul Timpson
Journal: Trends in cancer (2019)

Cancer-associated fibroblasts (CAFs) are one of the most significant components in the tumour microenvironment (TME), where they can perform several protumourigenic functions. Several studies have recently reported that CAFs are more heterogenous and plastic than was previously thought. As such, there has been a shift in the field to study CAF subpopulations and the emergent functions of these subsets in tumourigenesis. In this review, we explore how different aspects of CAF heterogeneity are defined and how these manifest in multiple cancers, with a focus on pancreatic ductal adenocarcinoma (PDAC). We also discuss therapeutic approaches to selectively target protumourigenic CAF functions, while avoiding normal fibroblasts, providing insight into the future of stromal targeting for the treatment of PDAC and other solid tumours.